Nutriband Inc. (NASDAQ: NTRB) CEO Gareth Sheridan has published a letter to shareholders to mark the fifth anniversary of the company's listing on the Nasdaq Capital Market, according to a press release distributed by InvestorWire. The letter reviews key milestones achieved since October 1, 2021, and outlines the company's near-term priorities as it seeks to advance its lead product candidate.
Since listing, Nutriband has moved AVERSA(TM) Fentanyl from feasibility studies through commercial manufacturing scale-up. The company has also expanded its patent protection and engaged with the U.S. Food and Drug Administration. AVERSA(TM) is an abuse-deterrent technology designed to be incorporated into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Looking ahead, Sheridan identified several key objectives. These include manufacturing clinical supplies for a Human Abuse Liability study, filing an Investigational New Drug application, initiating clinical studies, and advancing AVERSA(TM) Fentanyl toward a New Drug Application filing. These steps are critical for a company developing a product in the highly regulated pharmaceutical space, where clinical and regulatory milestones often drive valuation and investor sentiment.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) technology. The company's website is www.nutriband.com. Investors can find the latest news and updates relating to NTRB in the company's newsroom at https://ibn.fm/NTRB.
The announcement comes as InvestorWire, a specialized communications platform focused on wire-grade press release syndication, continues to support public and private companies. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact. It also provides social media distribution and tailored corporate communications solutions.
For readers, the shareholder letter provides transparency on Nutriband's strategic direction and the regulatory pathway for its lead asset. The company's progress with AVERSA(TM) Fentanyl could have implications for the broader opioid abuse-deterrent market if approved. However, investors should note that drug development carries inherent risks, and the company's forward-looking statements are subject to the terms of use and disclaimers on the InvestorWire website, available at https://www.InvestorWire.com/Disclaimer.
